Ambu A/S Q2 2025 Earnings Report

Ambu A/S EPS Results

• Actual EPS: $0.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ambu A/S Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ambu A/S Announcement Details

• Quarter: Q2 2025
• Date: 5/7/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Ambu A/S (OTCMKTS:AMBBY) is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. The company focuses on reducing the need to reprocess reusable equipment while supporting clinical procedures in areas such as endoscopy, anesthesia and patient monitoring.

Ambu’s product portfolio includes disposable endoscopes and related visualization systems, airway management products, anesthesia equipment and devices used for patient monitoring and diagnostics. Its endoscopy offerings are used in pulmonary, gastrointestinal and other clinical applications, while its anesthesia and airway products support the care of patients before, during and after medical procedures.

Founded in 1937 by Holger Hesse, Ambu is headquartered in Ballerup, Denmark, and serves healthcare markets internationally, including Europe, North America and the Asia-Pacific region. The company is led by Chief Executive Officer Britt Meelby Jensen, who has served in that role since 2023.